24 related articles for article (PubMed ID: 24616428)
1. Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.
Bhawal R; Oberg AL; Zhang S; Kohli M
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867043
[TBL] [Abstract][Full Text] [Related]
2. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring.
Loynachan CN; Soleimany AP; Dudani JS; Lin Y; Najer A; Bekdemir A; Chen Q; Bhatia SN; Stevens MM
Nat Nanotechnol; 2019 Sep; 14(9):883-890. PubMed ID: 31477801
[TBL] [Abstract][Full Text] [Related]
3. Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease.
Yepes D; Jacob A; Dauber M; Costina V; Hofheinz R; Neumaier M; Findeisen P
Int J Oncol; 2011 Jul; 39(1):145-54. PubMed ID: 21503574
[TBL] [Abstract][Full Text] [Related]
4. Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability.
Findeisen P; Costina V; Yepes D; Hofheinz R; Neumaier M
J Exp Clin Cancer Res; 2012 Jun; 31(1):56. PubMed ID: 22682081
[TBL] [Abstract][Full Text] [Related]
5. Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool.
Findeisen P; Peccerella T; Post S; Wenz F; Neumaier M
Rapid Commun Mass Spectrom; 2008 Apr; 22(8):1223-9. PubMed ID: 18348224
[TBL] [Abstract][Full Text] [Related]
6. Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology.
Peccerella T; Lukan N; Hofheinz R; Schadendorf D; Kostrezewa M; Neumaier M; Findeisen P
Clin Chem; 2010 Feb; 56(2):272-80. PubMed ID: 20110451
[TBL] [Abstract][Full Text] [Related]
7. MS-based monitoring of proteolytic decay of synthetic reporter peptides for quality control of plasma and serum specimens.
Findeisen P; Thumfart JO; Costina V; Hofheinz R; Neumaier M
Am J Clin Pathol; 2013 Sep; 140(3):314-23. PubMed ID: 23955449
[TBL] [Abstract][Full Text] [Related]
8. Multiplex profiling of tumor-associated proteolytic activity in serum of colorectal cancer patients.
Yepes D; Costina V; Pilz LR; Hofheinz R; Neumaier M; Findeisen P
Proteomics Clin Appl; 2014 Jun; 8(5-6):308-16. PubMed ID: 24616428
[TBL] [Abstract][Full Text] [Related]
9. Identification of biomarkers for colorectal cancer through proteomics-based approaches.
Tjalsma H
Expert Rev Proteomics; 2010 Dec; 7(6):879-95. PubMed ID: 21142889
[TBL] [Abstract][Full Text] [Related]
10. Functional protease profiling for diagnosis of malignant disease.
Findeisen P; Neumaier M
Proteomics Clin Appl; 2012 Jan; 6(1-2):60-78. PubMed ID: 22213637
[TBL] [Abstract][Full Text] [Related]
11. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare?
Reumer A; Maes E; Mertens I; Cho WC; Landuyt B; Valkenborg D; Schoofs L; Baggerman G
Expert Rev Proteomics; 2014 Aug; 11(4):449-63. PubMed ID: 24702250
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
